Photo: Benjamin L. Ebert, MD, PhD
Benjamin L. Ebert, MD, PhD
Year elected: 2011
Current membership category: Active
Dana-Farber Cancer Institute
Dana 1610
450 Brookline Avenue
Boston, MA 02115
United States of America
Phone: 617-632-1902

Honors and awards

ASCI | Stanley J. Korsmeyer Award (2021) For his contributions to the understanding of the genetics, biology, and treatment of myeloid malignancies. More
National Academy of Medicine (2018)

Society service

President, 2017–2018

Biographical statement

Dr. Benjamin Ebert is the Chair of Medical Oncology at the Dana-Farber Cancer Institute, the George P. Canellos, MD and Jean S. Canellos Professor of Medicine at Harvard Medical School, a Howard Hughes Medical Institute Investigator, and an Institute Member of the Broad Institute.

The Ebert laboratory focuses on the molecular basis and treatment of hematologic malignancies and its non-malignant precursor conditions, with a particular focus on myelodysplastic syndromes (MDS) and clonal hematopoiesis.  The Ebert laboratory demonstrated that lenalidomide, a derivative of thalidomide, binds the CRL4-CRBN E3 ubiquitin ligase and induces degradation of specific substrates.  Subsequent research from the Ebert laboratory has examined the potential of thalidomide analogs to induce degradation of a broad array of zinc finger transcription factors and other proteins, and to identify novel mechanisms of drug-induced protein degradation. 

Dr. Ebert received a bachelor's degree from Williams College and a doctorate from Oxford University as a Rhodes Scholar in the laboratory of Sir Peter Ratcliffe.He completed an M.D. from Harvard Medical School, a residency in internal medicine at Massachusetts General Hospital, and a fellowship in hematology/oncology at the Dana-Farber Cancer Institute.

Institutional affiliations

Harvard Medical School, Dana-Farber Cancer Institute (Primary)
William C. Hahn, MD, PhD is the representative at this institution.

Specialties

Hematology
Internal Medicine
Oncology